The Role of Epigenetic Control of Mitochondrial (Dys)Function in MASLD Onset and Progression

Metabolic dysfunction-associated steatotic fatty liver disease (MASLD), a novel definition for NAFLD, represents one of the most common causes of liver disease, and its incidence is increasing worldwide. It is characterized by a complex etiopathogenesis in which mitochondrial dysfunction exerts a pivotal role together with alteration of lipid metabolism, inflammation, and oxidative stress. Nutrients and bioactive compounds can influence such mechanisms so that changes in diet and lifestyle are regarded as important treatment strategies. Notably, natural compounds can exert their influence through changes of the epigenetic landscape, overall resulting in rewiring of molecular networks involved in cell and tissue homeostasis. Considering such information, the present review aims at providing evidence of epigenetic modifications occurring at mitochondria in response to natural and bioactive compounds in the context of liver (dys)function. For this purpose, recent studies reporting effects of compounds on mitochondria in the context of NAFLD/MASLD, as well as research showing alteration of DNA methylation and non-coding RNAs-related circuits occurring at liver mitochondria, will be illustrated. Overall, the present review will highlight the importance of understanding the bioactive compounds-dependent epigenetic modulation of mitochondria for improving the knowledge of MASLD and identifying biomarkers to be employed for effective preventative strategies or treatment protocols.

Automated summary

Metabolic dysfunction-associated steatotic fatty liver disease (MASLD), a novel definition for NAFLD, is one of the most common liver diseases with increasing incidence worldwide. Its complex etiopathogenesis involves mitochondrial dysfunction, altered lipid metabolism, inflammation, and oxidative stress. Changes in diet and lifestyle, as well as the influence of natural compounds, can modulate these mechanisms and improve the understanding and treatment of MASLD.